Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Diagnostics › Molecular Diagnostics › AstraZeneca's Lynparza Gives Survival Boost as Maintenance in Relapsed BRCA-Mutated Ovarian Cancer

AstraZeneca's Lynparza Gives Survival Boost as Maintenance in Relapsed BRCA-Mutated Ovarian Cancer

May 14, 2020
|
Andrea Anderson

NEW YORK – The PARP inhibitor olaparib (AstraZeneca/Merck's Lynparza) appears to extend overall survival when used as a post-chemotherapy maintenance treatment in women with advanced ovarian cancer who carry a BRCA1 or BRCA2 mutation, according to a final survival analysis from the Phase III SOLO2/ENGOT-ov21 trial.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
27
Featured Webinar

Oncology in the Time of COVID-19: Quantitative Proteomic Analysis of Anti-IL6 Treated Patients

Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Jun
08
Featured Webinar

Advancing Personalized Oncology with Transcriptomic Profiling and Mechanistic Modeling

Sponsored by
Qiagen

Cancer is a complex and heterogeneous disease requiring patient-specific molecular analysis to support treatment decisions.

Jun
16
Featured Webinar

Precision Oncology in Melanoma Patients Treated with Immunotherapy: Clinical and Technological Perspective

Sponsored by
Biognosys

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.

Jun
18
Featured Webinar

Disparities in Precision Oncology: Identifying Barriers and Moving Toward Solutions

Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019. 

What's Popular?

In Cancer

  1. AACR Study of Eli Lilly's Retevmo Shows Anti-Tumor Activity Across Cancers

  2. Grail Cancer Early Detection Test Performance Holds Steady as Q2 Launch Approaches

    Premium

  3. Tecentriq Response Analysis in MyPathway Study Bolsters Case for Higher TMB Cutoff

    Premium

  4. Cancer Dx Firm C2i Genomics Raises $100M in Financing

  5. Carisma Therapeutics Taps Into Innate Immune System to Extend CAR Therapy to Solid Tumors

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.